Mu Y, Zhou CH, Chen SF, Ding J, Zhang YX, Yang YP et al (2016) Effectiveness and safety of chemotherapy combined with cytokine-induced killer cell /dendritic cell-cytokine-induced killer cell therapy for treatment of gastric cancer in China: a systematic review and meta-analysis. Cytotherapy 18(9):1162–1177

Article  CAS  PubMed  Google Scholar 

Chen W, Zheng R, Zeng H, Zhang S, He J (2015) Annual report on status of cancer in China, 2011. Chin J Cancer Res = Chung-kuo yen cheng yen chiu 27(1):2–12

PubMed  Google Scholar 

Kalniņa Z, Meistere I, Kikuste I, Tolmanis I, Zayakin P, Linē A (2015) Emerging blood-based biomarkers for detection of gastric cancer. World J Gastroenterol 21(41):11636–11653

Article  PubMed  PubMed Central  Google Scholar 

Hamashima C (2014) Current issues and future perspectives of gastric cancer screening. World J Gastroenterol 20(38):13767–13774

Article  PubMed  PubMed Central  Google Scholar 

Digklia A, Wagner AD (2016) Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol 22(8):2403–2414

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC et al (2017) Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 8(8):Cd004064

PubMed  Google Scholar 

Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480(7378):480–489

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Zhao J, Zhang X, Gong C, Zhang J (2017) Targeted therapy with apatinib in a patient with relapsed small cell lung cancer: a case report and literature review. Medicine 96(50):e9259

Article  PubMed  PubMed Central  Google Scholar 

Fontanella C, Ongaro E, Bolzonello S, Guardascione M, Fasola G, Aprile G (2014) Clinical advances in the development of novel VEGFR2 inhibitors. Ann Transl Med 2(12):123

PubMed  PubMed Central  Google Scholar 

Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9(6):669–676

Article  CAS  PubMed  Google Scholar 

Lee SH, Jeong D, Han YS, Baek MJ (2015) Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res 89(1):1–8

Article  PubMed  PubMed Central  Google Scholar 

Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D et al (2016) Apatinib: a novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett 372(2):187–191

Article  CAS  PubMed  Google Scholar 

Zhang H (2015) Apatinib for molecular targeted therapy in tumor. Drug Des Dev Ther 9:6075–6081

Article  ADS  CAS  Google Scholar 

Bang Y-J, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet 376(9742):687–697

Article  CAS  Google Scholar 

Ychou M, Boige V, Pignon J-P, Conroy T, Bouché O, Lebreton G et al (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29(13):1715–1721

Article  CAS  PubMed  Google Scholar 

Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4(5):e180013

Article  PubMed  PubMed Central  Google Scholar 

Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao Y, Kato K et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 390(10111):2461–2471

Article  CAS  Google Scholar 

Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol 19(7):940–952

Article  PubMed  Google Scholar 

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929

Article  CAS  PubMed  Google Scholar 

Apolo AB, Infante JR, Balmanoukian A, Patel MR, Wang D, Kelly K et al (2017) Avelumab, an anti-programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase Ib study. J Clin Oncol Offic J Am Soc Clin Oncol 35(19):2117–2124

Article  CAS  Google Scholar 

Feng Y, Dai Y, Gong Z, Cheng JN, Zhang L, Sun C et al (2018) Association between angiogenesis and cytotoxic signatures in the tumor microenvironment of gastric cancer. Onco Targets Ther 11:2725–2733

Article  PubMed  PubMed Central  Google Scholar 

Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A (2019) Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer 18(1):60

Article  PubMed  PubMed Central  Google Scholar 

Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H et al (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet 392(10142):123–133

Article  CAS  Google Scholar 

Tabernero J, Bang Y-J, Fuchs CS, Ohtsu A, Kher U, Lam B et al (2016) KEYNOTE-062: Phase III study of pembrolizumab (MK-3475) alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. J Clin Oncol 34:TPS185-TPS185

Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. The Lancet 398(10294):27–40

Article  CAS  Google Scholar 

Zhou N, Zhang C, Liu D, Liu K, Wang G, Zhu H et al (2021) Apatinib in combination with S-1 as first-line treatment in patients with advanced metastatic gastric cancer: results from an open, exploratory, single-arm, phase II trial. Oncologist 26(3):e374–e381

Article  CAS  PubMed  Google Scholar 

Peng Z, Wei J, Wang F, Ying J, Deng Y, Gu K et al (2021) Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin. Cancer Res Offic J Am Assoc Cancer Res 27(11):3069–3078

Article  CAS  Google Scholar 

Tang Z, Wang Y, Yu Y, Cui Y, Liang L, Xu C et al (2022) Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Med 20(1):107

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xu C, Xie X, Kang N, Jiang H (2023) Neoadjuvant PD-1 inhibitor and apatinib combined with S-1 plus oxaliplatin for locally advanced gastric cancer patients: a multicentered, prospective, cohort study. J Cancer Res Clin Oncol 149(7):4091–4099

Article  CAS  PubMed  Google Scholar 

Pan L, Tian Y, Wang K, Tang J, Liu J, Zhang J et al (2022) Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial. J Gastrointest Oncol 13(6):3300–3313

Article  PubMed  PubMed Central  Google Scholar 

Xiong H, Li Y (2023) Neoadjuvant PD-1 inhibitor plus apatinib and chemotherapy versus apatinib plus chemotherapy versus chemotherapy alone in patients with locally advanced gastric cancer. Am J Cancer Res 13(8):3559–3570

PubMed  PubMed Central  Google Scholar 

Zhao D, Hou H, Zhang X (2018) Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther 11:4137–4147

Article  PubMed  PubMed Central  Google Scholar